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Breast implant-associated anaplastic large cell lymphoma (BIA-
ALCL) is a rare entity that has become known as a distinct clinical
condition recently. In general, BIA-ALCL patients with a history of
breast implants present with non-speciﬁc implant-related com-
plications, resulting in delayed diagnosis and appropriate treat-
ment because of the lack of awareness of BIA-ALCL. The cause and
pathogenesis have still not been identiﬁed, and there are no
evidence-based guidelines on how this condition should be
detected, treated or followed up because of the rarity of available
data. We present the ﬁrst published Danish case of anaplastic
lymphoma kinase negative BIA-ALCL, and review the current
literature to raise awareness of and discuss management options
for this rare clinical entity.
© 2015 The Authors. Published by Elsevier Ltd on behalf of British
Association of Plastic, Reconstructive and Aesthetic Surgeons. This
is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) is a rare clinical entity. It was
ﬁrst described in 1997, and 71 cases of BIA-ALCL have been identiﬁed in the recent literature.1 Other
cases have not been published, but have been reported by clinicians, resulting in a total of approxi-
mately 178 cases so far.2 When a potential link between ALCL and breast implants was suggested, as).
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cases of BIA-ALCL were identiﬁed.3 In general, BIA-ALCL patients with a history of breast implants
present with non-speciﬁc implant-related complications, resulting in delayed diagnosis and appro-
priate treatment because of the lack of awareness of BIA-ALCL. We present the ﬁrst published Danish
case of anaplastic lymphoma kinase (ALK) negative BIA-ALCL and review the current literature to raise
awareness of and discuss management options for this rare clinical entity.
Case report
A 42-year-old woman underwent bilateral cosmetic breast augmentation with McGhan silicone
implants in 2004. The patient had an uneventful postoperative period without any complications until
2011, when she presented with a 2-month history of spontaneous enlargement and tenderness of the
left breast. Therewas no history of trauma and no systemic symptoms at presentation. On examination,
the left breast was not tender but was slightly bigger than the right breast. There was no sign of
capsular contracture and no palpable lymphadenopathy. The ﬁndings of routine blood investigations
were normal. Breast ultrasonography and mammography revealed a localized collection of liquid
beyond the implant suggestive of implant leakage. Therefore, the patient underwent bilateral implant
removal. However, both implants were intact, and on the left side, approximately 1 L of serous ﬂuidwas
drained. Cultures were negative for bacterial growth. Excision of the ﬁbrous capsule around the im-
plants (capsulectomy) was not performed, because during that period, BIA-ALCL was not suspected
because of the non-speciﬁc symptoms. The implants were not replaced. During the following years, the
patient developed a ﬁrm distinct mass in the left breast. In 2015, mammography and ultrasonography
revealed a possible ﬁbrous capsular structure with seroma in the left breast. The patient underwent
left-sided capsulectomy with excision of a ﬁrm capsular structure containing a seroma (Figure. 1). On
histopathological analysis, ALCL, which was ALK negative, was found conﬁned within the ﬁbrous
capsule surrounding the implant. A PET-CT scan was performed and demonstrated no abnormality or
signs of systemic disease. Bonemarrow biopsy showed no evidence of lymphoma involvement, and the
ﬁndings of blood investigations were normal. The patient has remained clinically well postoperatively
without any B symptoms. She is currently receiving three series of cytotoxic CHOP chemotherapy and
radiation therapy under the care of hematologists.
Discussion
BIA-ALCL is conﬁned within the ﬁbrous capsule surrounding the implant. It is not a disease of the
breast parenchyma. Usually, patients present with various symptoms and clinical signs. Late-onset
seroma and periprosthetic effusion is a rather common presentation, and few patients present withFigure 1. The excised BIA-ALCL capsular tissue.
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contracture. ALCL is a CD30þ lymphoma that is a consequence of abnormal activation and proliferation
of T lymphocytes. ALCL is characterized as cutaneous or systemic, and the expression of the ALK gene
further classiﬁes the ALCL subtypes and determines the prognosis. The morphological and cytological
characteristics of BIA-ALCL are similar to those of ALK-negative systemic ALCL.4 However, ALK-negative
systemic ALCL has a poor prognosis, whereas ALK-negative BIA-ALCL is typically an indolent disease
with a much better prognosis.5 Almost all reported BIA-ALCL cases are negative for ALK.6 The differ-
ential diagnoses include chronic inﬂammation, poorly differentiated carcinoma and other lymphomas.
Additionally, the non-speciﬁc symptoms and lack of awareness of BIA-ALCL may easily cause delayed
diagnosis and appropriate treatment.
Textured implants are associated with more cases of ALCL than are smooth implants.2 Recently it
has been speculated whether textured implants could cause a passive potentiation, with the real
cause of BIA-ALCL being a bioﬁlm. Textured implants have an increased surface area for bacterial
bioﬁlm to form,7 and an infection of breast implants signiﬁcantly potentiates capsular contracture
and produces an increased T-cell response.8 There is assumed to be a possible link between bacterial
bioﬁlm and T-cell hyperplasia, and this has thus lately been accentuated as a possible cause of BIA-
ALCL. Therefore, it is suggested that prevention of infection may reduce the risk of capsular
contracture and consequently reduce the risk of lymphocyte activation and possible conversion to
BIA-ALCL.8
Despite increased vigilance for BIA-ALCL in recent years, important clinical issues associated
with the diagnosis and treatment of this rare entity remain unaddressed.9 No publication has
addressed whether reinsertion of the implant is safe or how the contralateral breast should be
managed, because in most cases unilateral disease has been reported. The cause and pathogenesis
have still not been identiﬁed, and there are no evidence-based guidelines on how this condition
should be detected, treated or followed up because of the rarity of available or accessible data.
However, it is suggested that any late seroma (more than 6e12 months after breast implantation) in
the absence of infection should undergo examination by ultrasonography and mammography to
identify a mass or lymph nodes that are suspicious for lymphoma. Afterwards, the seroma should be
aspirated and cytological analysis of the liquid, including culture, ﬂow cytometry and cell block,
should be performed.4,9 If the cytological analysis ﬁndings are negative, patients should be moni-
tored thoroughly for recurrence of seroma, and if a mass is present, a biopsy sample should be
obtained.9 Patients with the ALCL conﬁned within the capsule often have an indolent course and
good prognosis, responding well to capsulectomy and removal of the implant.2,9,10 In contrast,
patients who present with a distinct mass may have a more aggressive progression and poor
prognosis, requiring chemotherapy and/or radiation therapy.10 Postoperatively, a PET-CT scan and
bone marrow biopsy should be performed if BIA-ALCL is conﬁrmed in order to exclude systemic
disease. It is suggested patients receive clinical follow-up at least every 6 months for 5 years, with
breast ultrasonography for 2 years, and those who undergo reinsertion of the implant are advised to
undergo follow-up beyond 5 years.9
Even though ALK-negative BIA-ALCL is rare, the exact incidencemay be underestimated and it is not
unlikely that we may experience an escalation of incidence in the future. The current absence of
guidelines is due to the paucity of data and the lack of attention paid to this condition. Therefore, it is
essential to report all cases of BIA-ALCL to collect data worldwide and perform long-term follow-up. In
Denmark, surgeons report cases to the Danish Health and Medicines Authority, and since 2014, three
cases, including the case presented here, have been reported.11 This number is expected to increase
because of the increasing number of breast implant insertions and the increase in awareness of this
rare clinical entity.Acknowledgement
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